Sunesis Pharmaceuticals (FRA:RYIS) Total Stockholders Equity : €16.39 Mil (As of Dec. 2020)

View and export this data going back to 2007. Start your Free Trial

What is Sunesis Pharmaceuticals Total Stockholders Equity?

Sunesis Pharmaceuticals's Total Stockholders Equity for the quarter that ended in Dec. 2020 was €16.39 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Sunesis Pharmaceuticals's Book Value per Share for the quarter that ended in Dec. 2020 was €0.65. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Sunesis Pharmaceuticals's Debt-to-Equity for the quarter that ended in Dec. 2020 was 0.01.

Sunesis Pharmaceuticals Total Stockholders Equity Historical Data

The historical data trend for Sunesis Pharmaceuticals's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sunesis Pharmaceuticals Total Stockholders Equity Chart

Sunesis Pharmaceuticals Annual Data

Trend

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Total Stockholders Equity

Get a 7-Day Free Trial

19.93

18.21

3.51

24.79

16.39

Sunesis Pharmaceuticals Quarterly Data
	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20
Total Stockholders Equity	Get a 7-Day Free Trial															24.79	19.99	14.30	20.77	16.39

Sunesis Pharmaceuticals (FRA:RYIS) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Sunesis Pharmaceuticals's Book Value per Share for the quarter that ended in Dec. 2020 is

Book Value per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(16.388	-	4.558)	/	18.1083
	=	0.65

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Sunesis Pharmaceuticals's Debt-to-Equity for the quarter that ended in Dec. 2020 is

Debt-to-Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.224	+	0)	/	16.388
	=	0.01

Sunesis Pharmaceuticals Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Sunesis Pharmaceuticals's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Sunesis Pharmaceuticals (FRA:RYIS) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sunesis Pharmaceuticals Inc (FRA:RYIS) » Definitions » Total Stockholders Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

395 Oyster Point Boulevard, Suite 400, South San Francisco, CA, USA, 94080

Website

http://www.sunesis.com

Sunesis Pharmaceuticals Inc is a US-based biopharmaceutical company. It focuses on the development and commercialization of its pipeline of oncology therapeutics for the treatment of solid and hematologic cancers. The product portfolio of the company includes Vosaroxin which is an anticancer quinolone derivative for the treatment of acute myeloid leukemia (AML). The company's other kinase inhibitor pipeline includes TAK-580, SNS-062, and SNS-229. Further, the firm's activities include conducting research and development internally and through corporate collaborators, in-licensing and out-licensing pharmaceutical compounds and technology, conducting clinical trials and raising capital. The firm derives substantially the majority of revenue from license and collaboration agreements.

Sunesis Pharmaceuticals (FRA:RYIS) Headlines

No Headlines